DESCOVY
5803
After years of worrying about kidney problems and bone health issues, now we have the new PrEP that is safer for both kidneys and bone health.
What is DESCOVY?
Emtricitabine/tenofovir alafenamide (FTC/TAF)
Descovy is the new PrEP pill that contains emtricitabine along with tenofovir alafenamide (TAF) instead of tenofovir disoproxil fumarate (TDF). F/TAF can deliver higher concentrations of tenofovir into cells, achieves protective levels more quickly, and sustains those levels longer than F/TDF. For these reasons, F/TAF may be more effective than F/TDF for individuals who occasionally miss doses.
In the DISCOVER study, which showed that F/TAF was "non-inferior" to F/TDF for PrEP (but did not establish that it was "superior"), there were more HIV infections among participants taking F/TDF (11 infections) compared to those taking F/TAF (6 infections; these figures exclude individuals with suspected acute HIV infections at baseline). However, this difference was not statistically significant. While there is some debate over whether F/TAF is truly "more effective" than F/TDF for PrEP, there is currently no evidence indicating that Descovy is more effective than Truvada in preventing HIV as of January 2021.
One advantage of TAF is that it does not lead to the same level of kidney issues or a decrease in bone density associated with TDF. Both Descovy and Truvada are recommended as first-line therapies in HIV treatment guidelines globally, and both are also approved for the treatment of hepatitis B.
Seven years after the approval of Truvada (F/TDF) for HIV prevention as PrEP, we now have an additional option. On October 3, 2019, the U.S. Food and Drug Administration (FDA) approved Descovy (F/TAF) as PrEP for individuals who are HIV-negative and at risk of acquiring HIV through sexual contact.
Efficacy & Research
The DISCOVER study found that F/TAF was “non-inferior” to F/TDF for PrEP but did not prove it was superior. The study reported 11 HIV infections in the F/TDF group and 6 in the F/TAF group (excluding baseline acute HIV cases), though this difference was not statistically significant.
As of January 2021, there is no conclusive evidence that Descovy is more effective than Truvada in preventing HIV.
Approval & Availability
The U.S. FDA approved Descovy for PrEP on October 3, 2019, providing an alternative to Truvada, which was approved seven years earlier. Descovy is approved for individuals at risk of HIV through sexual contact.
Standard Dosage:
- Dose: One tablet daily, with or without food.
- Composition: 200 mg emtricitabine and 25 mg tenofovir alafenamide.
- Eligibility: Suitable for adults and children weighing at least 25 kg (55 lbs).
- Tablet Form: Crushing or splitting is not recommended due to its bitter taste and unknown impact on efficacy.
- Missed Dose: Take it as soon as possible unless it’s close to the next dose. Do not double up.
- Contraindications: Not recommended for those with a creatinine clearance (CrCl) below 30 mL/min or undergoing dialysis. In children under 77 lbs, Descovy should not be combined with boosted HIV protease inhibitors.
Important Considerations
- Do not combine Descovy with other antiviral medications unless prescribed.
- Many single-tablet regimens (STRs) already contain TAF.
- Drug interactions are possible; inform your doctor about all medications, including over-the-counter drugs.
Descovy offers a safer alternative to TDF-containing PrEP, with fewer kidney and bone-related side effects, making it a preferred choice for many at risk of HIV.
If you are looking for a generic new PrEP
For more information about the medication and ordering process, please contact us at pulseliving@pulse-clinic.com or chat with us on your preferred platform.
Trust PULSE CLINIC to take care of your health like other 45000 people from over 130 countries. We provide discreet professional service with high privacy. Here to help, not to judge.
PrEP Medication Prices
| PrEP Options | Special Promotion | ||
| PrEP Pills |
1 bottle | 6 bottles (6 months) | 12 bottles (12 months) |
| Descovy | 3,150 THB | 18,000 THB | 36,000 THB |
| Generic Descovy | 1,640 THB | 9,000 THB | 18,000 THB |
| Teno-Em (Generic Truvada) | 1,250 THB | 7,500 THB | 12,000 THB |
| Tenof-Em (Generic Truvada) | 1,050 THB | 6,300 THB | 10,900 THB |
| PrEP Injection | 3 injections (5 months) | 5 injections (9 months) | 7 injections (13 months) |
| Apretude (Cabotegravir) | 58,000 THB | 95,000 THB | 126,000 THB |
Get your Descovy for HIV PrEP today!
If you are looking for a new generic PrEP.
For more information about the medication and ordering process, please contact us at pulseliving@pulse-clinic.com or chat with us on your preferred platform.
+66-84-226-2569 
@pulserx 
PulseClinic
What is Truvada vs. Descovy?
| Category | Truvada | Descovy |
| FDA Approval | August 2, 2004 | April 4, 2016 |
| Approved as PrEP | 2012 | October 3, 2019 |
| Generic Name | Emtricitabine 200mg + Tenofovir Disoproxil Fumarate (TDF) 300mg | Emtricitabine 200mg + Tenofovir Alafenamide (TAF) 25mg |
| Indications as PrEP | For at-risk adults and adolescents weighing at least 35 kg | For at-risk adult and adolescent men and transgender women weighing at least 35 kg |
| Indications for Treatment | HIV-1 Infection in adults and pediatric patients weighing at least 17 kg (in combination with other antiretroviral agents) | HIV-1 Infection in adults and pediatric patients weighing at least 25 kg (in combination with other antiretroviral agents) |
| Pill Size | Larger | Smaller |
| Kidney Problems | Occur around 3% of old PrEP users | Lower risk due to TAF’s targeted delivery and lower plasma concentrations |
| Good For | Younger users; users with good kidney function | Older users; individuals with compromised kidney function or concerns about side effects |
| Recommended for Daily Dose? | Yes, Truvada and its generics are effective for daily dosing | Yes, Descovy and its generics are effective for daily dosing |
| Recommended for PrEP on Demand (2-1-1)? | Yes, Truvada and its generics are suitable for on-demand use | No, as large-scale studies for on-demand use with Descovy are not available |
| Recommended for Vaginal Sex? | Yes | No, as its efficacy for individuals assigned female at birth engaging in vaginal sex has not been studied |
| Recommended for Anal Sex? | Yes | Yes |
Benefits of TAF
One significant advantage of TAF is its reduced risk of kidney complications and bone density loss compared to TDF. Both DESCOVY and Truvada are globally recommended as first-line therapies for HIV prevention and treatment and are also approved for managing hepatitis B.
Seven years after Truvada's approval as the first PrEP option, the U.S. Food and Drug Administration (FDA) approved DESCOVY for PrEP on October 3, 2019. This approval provides an additional option for HIV-negative individuals at risk of contracting HIV through sexual activity.
Get Your HIV PrEP Treatment Medication Online Now Today!
Enjoy fuss-free, discreet packaging with fast, worldwide shipping from PULSE. For more details and the ordering process, contact us at pulseliving@pulse-clinic.com or chat with us on your preferred platform.
+66-84-226-2569 @pulserx PulseClinic
Take home message
It’s evident that PrEP alternatives are advancing: In the coming years, patients can look forward to a variety of options, including generics, injectables, implants, and more. You have the freedom to choose what works best for your health and lifestyle. Reach out to our clinic today to discuss your health and the prevention strategies that suit you best. We are here to help year-round.
I have my prescription and I want to order now, TAKE ME THERE !